Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system

Journal of Pharmaceutical Sciences

Volumn 98, Issue 7, 2009, Pages 2501-2515

  Dhuria, Shyeilla V ^a,b   Hanson, Leah R ^b   Frey II, William H ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

Absorption; Blood brain barrier; Brain; Drug targeting; Hypocretin; Narcolepsy; Nasal drug delivery; Orexin; Peptide delivery; Pharmacokinetics

Indexed keywords

OREXIN A;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN REGION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INFUSION; DRUG TARGETING; DRUG TRANSPORT; MALE; NONHUMAN; OLFACTORY BULB; OLFACTORY NERVE; RAT; SPINAL CORD; TRIGEMINAL NERVE;

EID: 67650172577     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21604     Document Type: Article

References (59)

1. Sakurai T. 2002. Roles of orexins in regulation of feeding and wakefulness. Neuroreport 13:987-995. (Pubitemid 34587726)
2. Sweet DC, Levine AS, Billington CJ, Kotz CM. 1999. Feeding response to central orexins. Brain Res 821:535-538.
3. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, Arch JR, Buckingham RE, Haynes AC, Carr SA, Annan RS, McNulty DE, Liu WS, Terrett JA, Elshourbagy NA, Bergsma DJ, Yanagisawa M. 1998. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585. (Pubitemid 28101119)
4. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M. 1999. Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation. Cell 98:437-451. (Pubitemid 29402482)
5. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T. 2001. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345-354. (Pubitemid 32530580)
6. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, Yanagisawa M. 2004. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron- ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 101:4649-4654. (Pubitemid 38437465)
7. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E. 2000. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991-997.
8. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM. 2000. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469-474. (Pubitemid 30951849)
9. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. 2003. Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26:953-959. (Pubitemid 39619754)
10. Barreiro ML, Pineda R, Gaytan F, Archanco M, Burrell MA, Castellano JM, Hakovirta H, Nurmio M, Pinilla L, Aguilar E, Toppari J, Dieguez C, Tena- Sempere M. 2005. Pattern of orexin expression and direct biological actions of orexin-a in rat testis. Endocrinology 146:5164-5175. (Pubitemid 41653030)
11. Johren O, Neidert SJ, Kummer M, Dendorfer A, Dominiak P. 2001. Prepro-orexin and orexin receptor mRNAs are differentially expressed in peripheral tissues of male and female rats. Endocrinology 142:3324-3331. (Pubitemid 32681736)
12. Ehrstrom M, Gustafsson T, Finn A, Kirchgessner A, Gryback P, Jacobsson H, Hellstrom PM, Naslund E. 2005. Inhibitory effect of exogenous orexin a on gastric emptying, plasma leptin, and the distribution of orexin and orexin receptors in the gut and pancreas in man. J Clin Endocrinol Metab 90:2370-2377. (Pubitemid 40586287)
13. Dhanda DS, Frey WH II, Leopold D, Kompella UB. 2005. Approaches for drug deposition in the human olfactory epithelium. Drug Deliv Technol 5:64-72.
14. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH II. 2004. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127:481-496. (Pubitemid 38950662)
15. Vyas TK, Shahiwala A, Marathe S, Misra A. 2005. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2:165-175. (Pubitemid 40488626)
16. Hanson LR, Martinez PM, Taheri S, Kamsheh L, Mignot E, Frey WH. 2004. Intranasal administration of hypocretin 1 (orexin A) bypasses the bloodbrain barrier&targets the brain: A new strategy for the treatment of narcolepsy. Drug Deliv Technol 4:66-70.
17. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. 2007. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27:14239-14247.
18. Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D. 2008. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain. DOI: 10.1093/brain/awn 193.
19. Nishino S, Ripley B, Overeem S, Nevsimalova S, Lammers GJ, Vankova J, Okun M, Rogers W, Brooks S, Mignot E. 2001. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 50:381-388. (Pubitemid 32848741)
20. Banks WA, During MJ, Niehoff ML. 2004. Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 309:469-475. (Pubitemid 38542596)
21. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL. 2002. Sniffing neuropeptides: A transnasal approach to the human brain. Nat Neurosci 5:514-516. (Pubitemid 34568991)
22. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, Cattaneo A. 2005. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 102: 3811-3816. (Pubitemid 40360709)
23. Liu XF, Fawcett JR, Hanson LR, FreyWH II. 2004. The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal insulin-like growth factor-I in rats. J Stroke Cerebrovasc Dis 13:16-23. (Pubitemid 38419175)
24. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR, Frey WH II. 2004. Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: A non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 151:66-77. (Pubitemid 38624401)
25. Matsuoka Y, Gray AJ, Hirata-Fukae C, Minami SS, Waterhouse EG, Mattson MP, LaFerla FM, Gozes I, Aisen PS. 2007. Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31:165-170. (Pubitemid 46742300)
26. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S. 2008. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448.
27. Benedict C, Kern W, Schultes B, Born J, Hallschmid M. 2008. Differential sensitivity of men and women to anorexigenic and memory improving effects of intranasal insulin. J Clin Endocrinol Metab 93:1339-1344.
28. Paxinos G, Watson C. 1997. The rat brain in stereotaxic coordinates. 3rd edition. San Diego: Academic Press.
29. Dufes C, Olivier JC, Gaillard F, Gaillard A, Couet W, Muller JM. 2003. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255:87-97. (Pubitemid 36369593)
30. Bailer AJ. 1988. Testing for the equality of area under the curves when using destructive measurement techniques. J Pharmacokinet Biopharm 16: 303-309. (Pubitemid 18192401)
31. Chow HS, Chen Z, Matsuura GT. 1999. Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci 88:754-758. (Pubitemid 29398540)
32. Hunt CA, MacGregor RD, Siegel RA. 1986. Engineering targeting in vivo drug delivery: I. The physiological and physicohemical governing opportunities and limitations. Pharm Res 333-344.
33. Zhang Q, Jiang X, Jiang W, Lu W, Su L, Shi Z. 2004. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 275:85-96. (Pubitemid 38481522)
34. van den Berg MP, Verhoef JC, Romeijn SG, Merkus FW. 2004. Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 58:131-135. (Pubitemid 38781013)
35. Kastin AJ, Akerstrom V. 1999. Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 289:219-223. (Pubitemid 29156032)
36. Pardridge WM. 2005. The blood-brain barrier: Bottleneck in brain drug development. NeuroRx 2:3-14. (Pubitemid 40128022)
37. Chen XQ, Fawcett JR, Rahman YE, Ala TA, Frey IW. 1998. Delivery of nerve growth factor to the brain via the olfactory pathway. J Alzheimers Dis 1:35-44. (Pubitemid 30832306)
38. Westin U, Piras E, Jansson B, Bergstrom U, Dahlin M, Brittebo E, Bjork E. 2005. Transfer of morphine along the olfactory pathway to the central nervous system after nasal administration to rodents. Eur J Pharm Sci 24:565-573. (Pubitemid 40387270)
39. Sakane T, Akizuki M, Yoshida M, Yamashita S, Nadai T, Hashida M, Sezaki H. 1991. Transport of cephalexin to the cerebrospinal fluid directly from the nasal cavity. J Pharm Pharmacol 43: 449-451.
40. Kida S, Pantazis A, Weller RO. 1993. CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol 19:480-488.
41. Bradbury MW, Westrop RJ. 1983. Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J Physiol 339:519-534.
42. Johnston M, Zakharov A, Papaiconomou C, Salmasi G, Armstrong D. 2004. Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 1:2. (Pubitemid 44848568)
43. Walter BA, Valera VA, Takahashi S, Ushiki T. 2006. The olfactory route for cerebrospinal fluid drainage into the peripheral lymphatic system. Neuropathol Appl Neurobiol 32:388-396. (Pubitemid 44015580)
44. Nagra G, Koh L, Zakharov A, Armstrong D, Johnston M. 2006. Quantification of cerebrospinal fluid transport across the cribriform plate into lymphatics in rats. Am J Physiol 291:R1383-R1389. (Pubitemid 44776713)
45. Cserr HF, Harling-Berg CJ, Knopf PM. 1992. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol 2:269-276.
46. Hadaczek P, Yamashita Y, Mirek H, Tamas L, Bohn MC, Noble C, Park JW, Bankiewicz K. 2006. The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 14:69-78. (Pubitemid 43922142)
47. Thorne RG, Hanson LR, Ross TM, Tung D, Frey WH II. 2008. Delivery of interferon-b to the monkey nervous system following intranasal administration. Neuroscience. 152:785-797.
48. Redman LW, Tustanoff ER. 1984. Iodination of [Tyr8]-bradykinin-comparison of chloramine-T and lactoperoxidase techniques. J Immunoassay 5:29-57. (Pubitemid 14109880)
49. Wajchenberg BL, Pinto H, Torres de Toledo e Souza I, Lerario AC, Ribeiro Pieroni R. 1978. Preparation of iodine-125-labeled insulin for radioimmunoassay: Comparison of lactoperoxidase and chloramine- T iodination. J Nucl Med 19:900-905.
50. Baumann G, Amburn K. 1986. The autodecomposition of radiolabeled human growth hormone. J Immunoassay 7:139-149. (Pubitemid 17171711)
51. Alcalay RN, Giladi E, Pick CG, Gozes I. 2004. Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze. Neurosci Lett 361:128-131. (Pubitemid 38609233)
52. Gozes I, Giladi E, Pinhasov A, Bardea A, Brenneman DE. 2000. Activity-dependent neurotrophic factor: Intranasal administration of femtomolar- acting peptides improve performance in a water maze. J Pharmacol Exp Ther 293:1091-1098.
53. Friedman LF, Zeitzer JM, Lin L, Hoff D, Mignot E, Peskind ER, Yesavage JA. 2007. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 68:793-794.
54. Thannickal TC, Lai YY, Siegel JM. 2007. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130(Pt 6): 1586-1595. (Pubitemid 47355933)
55. Allard JS, Tizabi Y, Shaffery JP, Trouth CO, Manaye K. 2004. Stereological analysis of the hypothalamic hypocretin/orexin neurons in an animal model of depression. Neuropeptides 38:311-315. (Pubitemid 39298731)
56. Hallschmid M, Born J. 2008. Revealing the potential of intranasally administered orexin a (hypocretin- 1). Mol Interv 8:133-137.
57. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey Ii WH, Craft S. 2008. Intranasal insulin administration dosedependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimers Dis 13:323-331. (Pubitemid 352039034)
58. Yamada K, Hasegawa M, Kametani S, Ito S. 2007. Nose-to-brain delivery of TS-002, prostaglandin D2 analogue. J Drug Target 15:59-66. (Pubitemid 47161332)
59. Gozes I, Divinski I. 2007. NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 4:507-509. (Pubitemid 350248382)